Decrease of circulating hematopoietic progenitor cells During interleukin-2 treatment is associated with an increase of vascular cell adhesion molecule-1, a critical molecule for progenitor cell adhesion.
Administration of interleukin-2 (IL-2) to cancer patients has been shown to transiently decrease the number of circulating hematopoietic progenitor cells, but the mechanism of this phenomenon is unknown. Recently, the interaction of vascular adhesion molecule-1 (VCAM-1) with leukocyte very late antigen-4 (VLA-4) has been demonstrated to play a crucial role in the adhesion of progenitor cells to bone marrow stromal elements. Cytokine induced upregulation of VCAM-1 leads to increased binding of progenitor cells to stromal cells in vitro, and inhibition of this interaction by monoclonal antibodies is associated with marked progenitor cell mobilisation in vivo. In the present study we serially determined peripheral blood progenitor cell numbers during IL-2 treatment (10 courses) in 6 cancer patients and determined in parallel levels of soluble VCAM-1 as a surrogate marker for the in vivo activation of this molecule. Our data indicate that continuous intravenous administration of IL-2 for 5 days leads to a marked decrease of circulating progenitor cells associated with a substantial increase of circulating VCAM-1. Circulating myeloid progenitor cells (CFU-GM) dropped from a mean value of 167 +/- 187 / ml pre IL-2 to 16 +/- 15 / ml on day 3 (p < 0.01). Similarily, mean erythroid progenitors (BFU-E) decreased from 282 +/- 204 / ml before IL-2 administration to 86 +/- 61 / ml on day 3 (p < 0.005). In contrast, soluble VCAM-1 rose from a mean value of 1814 +/- 451 ng/ml before to 4607 +/- 736 ng/ml at the end of IL-2 therapy (p < 0.0001). Sera from IL-2 treated patients did not inhibit hematopoietic colony formation from normal bone marrow. These results suggest redistribution and increased adhesion of progenitor cells to stromal and/or endothelial elements during IL-2 via the VCAM-1/VLA-4 interaction as a possible mechanism for the decrease of circulating progenitor cells during IL-2 therapy.
Locker
G J
GJ
Department of Internal Medicine I, Division of Oncology, University Hospital of Vienna, Vienna, Austria. gottfried.locker@akh-wien.ac.at
Stoiser
B
B
Losert
H
H
Wenzel
C
C
Ohler
L
L
Kabrna
E
E
Geissler
K
K
D000328:Adult; D000368:Aged; D001773:Blood Cells / Q000166:cytology / Q000276:immunology; D001854:Bone Marrow Cells / Q000187:drug effects; D002448:Cell Adhesion; D005260:Female; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D007167:Immunotherapy; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D012995:Solubility; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood* / Q000187:drug effects* / Q000502:physiology
D007376:Interleukin-2; D019010:Vascular Cell Adhesion Molecule-1